We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01702922
Recruitment Status : Recruiting
First Posted : October 10, 2012
Last Update Posted : October 19, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:


- Serious illnesses like cancer or Neurofibromatosis Type 1 (NF1), can cause high levels of stress in a family. When a child is diagnosed with cancer or NF1, parents face numerous stressors, each of which can strain relationships. Many parents struggle to effectively cope with the changes in parenting roles that often accompany treatment of childhood cancer or NF1. How parents cope with this stress can influence whether the relationship is strengthened or weakened. Stress levels can also affect the care of the child who has cancer or NF1. Researchers want to better understand the critical time points and events during the child s treatment when the relationship becomes most stressed and/or strengthened.


- To study how stress affects the relationship between parents who have a child with cancer or Neurofibromatosis Type 1 (NF1).


  • Parents of a child (between 1 and 24 years of age) who has been diagnosed with cancer or NF1.
  • Participants must have been in a partnership at the time the child was diagnosed with cancer or NF1. At least one of the parents must be a biological or legal parent of the child.


  • Participants will fill out a questionnaire either online or by paper and pencil. It will take about 20 minutes to complete. The questions ask about the experience of dealing with a child s cancer OR NF1 diagnosis and how it affects participants relationship with their spouse/partner.
  • Some participants will also have an in-depth interview. It will last about an hour. It will ask further questions about the cancer OR NF1 diagnosis and treatment and its effect on the relationship.
  • Treatment will not be provided as part of this study.

Condition or disease
Parents of Children With Cancer Parents of Children With NF1 Parents of Children With Neurofibromatosis Type I

  Show Detailed Description

Study Design

Study Type : Observational
Estimated Enrollment : 360 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Understanding the Perceived Influence of Childhood Cancer and NF1 on the Parents' Marital/Partner Relationship: A Descriptive Study
Study Start Date : September 11, 2012

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :
  1. Stress impact communication [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Positive dyadic coping and strengthening marital relationship [ Time Frame: 3 months ]
  2. Stressful timepoints [ Time Frame: 3 months ]
  3. Compare the perceptions of various subgroups in the sample [ Time Frame: 3 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Participants must have been in a partnership at the time the child was diagnosed with cancer or NF1. At least one participant must be the biological/legal parent of the child; the partner may or may not be a biological/legal parent. Divorced parents who separated or divorced during or after the child s treatment can participate in this study.
  • The participant s child must be between 1-24 years of age.
  • Participants must be 18 years of age or older.
  • Participants must be fluent in the English language.
  • The participant s child must have been:

    • diagnosed with cancer at least 3 months prior to enrollment on this study and be currently receiving treatment OR
    • have completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years OR
    • diagnosed with NF1 at least 3 months prior to enrollment on this study
  • Participants must verbalize willingness to discuss the impact of their child s cancer or NF1 diagnosis on their relationship.
  • Able to understand and willing to sign the informed consent document.


  • Parents of a child with cancer OR NF1 without a partner/spouse during the child s treatment for cancer or NF1 are excluded from this study.
  • Parents who were not living with the child during his or her treatment and involved in the child s care.
  • Parents of children who are enrolled in hospice care.
  • Presence of psychotic symptoms or severe psychological distress, which in the judgment of the Principal or Associate Investigator would compromise the participants ability to engage in the study procedures or results.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01702922

Contact: Lori Wiener, Ph.D. (301) 451-9148 wienerl@pbmac.nci.nih.gov

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937      
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Alberta's Children's Hospital Hematology/Oncology/Transplant Program Recruiting
Alberta, Canada, T2L 2A6
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Lori Wiener, Ph.D. National Cancer Institute (NCI)
More Information

Additional Information:
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01702922     History of Changes
Other Study ID Numbers: 120206
First Posted: October 10, 2012    Key Record Dates
Last Update Posted: October 19, 2017
Last Verified: February 24, 2017

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Dyadic Coping

Additional relevant MeSH terms:
Neurofibromatosis 1
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Peripheral Nervous System Neoplasms
Nervous System Neoplasms
Peripheral Nervous System Diseases
Neuromuscular Diseases